Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD263 (TRAIL-R3) Monoclonal Antibody (TRAIL-R3-02), FITC
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA110161
Description
This antibody reacts with TRAIL-R3, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.
TRAIL-R3 (CD263) is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.
Specifications
CD263 (TRAIL-R3) | |
Monoclonal | |
0.1 mg/mL | |
PBS with 0.2% BSA and 15mM sodium azide; pH 7.4 | |
O14798 | |
TNFRSF10C | |
TRAIL-R3-hIgGhc fusion protein. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
Flow Cytometry | |
TRAIL-R3-02 | |
FITC | |
TNFRSF10C | |
Antagonist decoy receptor for TRAIL/Apo-2L; CD263; cytotoxic TRAIL receptor-3; DCR1; DCR1-TNFR; Decoy receptor 1; decoy TRAIL receptor without death domain; LIT; lymphocyte inhibitor of TRAIL; MGC149501; MGC149502; TNF receptor superfamily member 10c; TNF-related apoptosis-inducing ligand receptor 3; TNFRSF10C; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAILR3; TRAIL-R3; TRID; Tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain; UNQ321/PRO366 | |
Mouse | |
Size-exclusion Chromatography | |
RUO | |
8794 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction